Eli Lilly & Company Foundation

Eli Lilly & Company Foundation

The Eli Lilly & Company Foundation was established in 1968 as the tax-exempt private foundation of the Indiana-based pharmaceutical corporation. Its board is populated by senior Eli Lilly executives, including CEO David Ricks as chair, and its day-to-day operations are led by Una Osili, appointed Executive Director of Philanthropy, Strategy and Operations in 2025. The foundation is funded by its parent corporation and maintains a corporate stock and bond portfolio managed from Indianapolis. Tiffany Benjamin, a former president of the foundation, previously stewarded its grantmaking strategy before transitioning out of the role. The foundation's grantmaking operates in two distinct lanes: improving healthcare access in low and middle-income countries and strengthening public education in the United States. The domestic education focus is weighted toward math and science programming. The foundation's estimated $3 million in assets places it in a cohort of corporate foundations that function less as perpetual endowments and more as annual flow-through vehicles for corporate-donated funds. Unlike private foundations with diversified, permanent capital, the Eli Lilly & Company Foundation's portfolio is concentrated in corporate stock and bond holdings, making its financial scale directly tied to the parent company's treasury allocations. Geographic deployment covers the United States and select low and middle-income countries, with specific country programs determined by the parent company's operational and disease-burden footprint. Team size and total grant deployment are not publicly disaggregated from Eli Lilly and Company's broader corporate responsibility reporting. The foundation's board includes senior Eli Lilly executives beyond Ricks — Anat Hakim, Anne White, and Daniel Skovronsky — reflecting tight integration with the parent's strategic priorities. In 2025, the foundation appointed Una Osili, a philanthropy academic and practitioner, to lead its strategy and operations, signaling a potential emphasis on measurable outcomes and evidence-based grantmaking. The foundation participates in the Indiana Philanthropy Alliance and the Council on Foundations, connecting it to peer institutional funders and sector best practices. The foundation's structural differentiator is its status as a corporate foundation deeply embedded inside a single publicly traded pharmaceutical company. This architecture means programmatic priorities — disease areas, country selection, educational focus — are heavily shaped by Eli Lilly's therapeutic areas and commercial footprint, making it less independent than a family foundation of comparable size. Its grantmaking is not endowment-driven but instead operates as an annual allocation from the parent's treasury, a model that provides flexibility but limits multi-year programmatic commitments absent earmarked corporate pledges.